MICHAEL D WHITE
Athletic Trainer in Framingham, MA
License number
Massachusetts 2061
Issued Date
Nov 23, 2009
Expiration Date
Feb 21, 2017
Type
Athletic Trainer
Address
Address
Framingham, MA 01702
Personal information
See more information about MICHAEL D WHITE at radaris.comName
Address
Phone
498 Lincoln St, Duxbury, MA 02332
4 Duck Pond Rd APT 203, Beverly, MA 01915
4 Kettle Way, Dracut, MA 01826
4 Winifreds Way, Rutland, MA 01543
4 Princess Pine Ln, Milford, MA 01757
Professional information
See more information about MICHAEL D WHITE at trustoria.com
Human Antibodies That Bind Human Tnf.alpha.
Human Antibodies That Bind Human Tnf.alpha.
US Patent:
6090382, Jul 18, 2000
Filed:
Feb 9, 1996
Appl. No.:
8/599226
Inventors:
Jochen G. Salfeld - North Grafton MA
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westboro MA
Boris Labkovsky - Framingham MA
John A. Mankovich - Andover MA
Brian T. McGuinness - Hauxton, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Shrewsbury MA
David Schoenhaut - Clifton NJ
Tristan J. Vaughan - Impington, GB
Michael White - Framingham MA
Alison J. Wilton - Cambridge, GB
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westboro MA
Boris Labkovsky - Framingham MA
John A. Mankovich - Andover MA
Brian T. McGuinness - Hauxton, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Shrewsbury MA
David Schoenhaut - Clifton NJ
Tristan J. Vaughan - Impington, GB
Michael White - Framingham MA
Alison J. Wilton - Cambridge, GB
Assignee:
BASF Aktiengesellschaft
International Classification:
A61K 39395, C07K 1624
US Classification:
4241331
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor. alpha. (hTNF. alpha. ) are disclosed. These antibodies have high affinity for hTNF. alpha. (e. g. , K. sub. d =10. sup. -8 M or less), a slow off rate for hTNF. alpha. dissociation (e. g. , K. sub. off =10. sup. -3 sec. sup. -1 or less) and neutralize hTNF. alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF. alpha. and for inhibiting hTNF. alpha. activity, e. g. , in a human subject suffering from a disorder in which hTNF. alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Human Antibodies That Bind Human Tnfα And Methods Of Using Same
Human Antibodies That Bind Human Tnfα And Methods Of Using Same
US Patent:
8414894, Apr 9, 2013
Filed:
Dec 30, 2011
Appl. No.:
13/340805
Inventors:
Jochen G. Salfeld - North Grafton MA, US
John A. Mankovich - Andover MA, US
Deborah J. Allen - London, GB
Hendricus R.J.M. Hoogenboom - Hasselt, BE
Boris Labkovsky - Framingham MA, US
Brian T. McGuinness - Cambridge, GB
Paul Sakorafas - Newtown Highlands MA, US
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB
Zehra Kaymakcalan - Westboro MA, US
Andrew J. Roberts - Cambridge, GB
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
John A. Mankovich - Andover MA, US
Deborah J. Allen - London, GB
Hendricus R.J.M. Hoogenboom - Hasselt, BE
Boris Labkovsky - Framingham MA, US
Brian T. McGuinness - Cambridge, GB
Paul Sakorafas - Newtown Highlands MA, US
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB
Zehra Kaymakcalan - Westboro MA, US
Andrew J. Roberts - Cambridge, GB
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Assignee:
Abbott Biotechnology Ltd. - Hamilton
International Classification:
A61K 39/395, C07K 16/00, G01N 33/53
US Classification:
4241421, 4241451, 4241581, 4241781, 435 71, 435 77, 435 79, 53038815, 53038823, 5303911
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Antibodies That Bind Il-18 And Methods Of Inhibiting Il-18 Activity
Antibodies That Bind Il-18 And Methods Of Inhibiting Il-18 Activity
US Patent:
2011000, Jan 13, 2011
Filed:
May 24, 2010
Appl. No.:
12/786095
Inventors:
Richard W. Dixon - Jefferson MA, US
Michael Roguska - Ashland MA, US
Michael White - Framingham MA, US
Boris Labkovsky - Marlborough MA, US
Jochen Salfeld - North Grafton MA, US
Alexander Robert Duncan - Little Shelford, GB
Simon Mark Brocklehurst - Fulbourn, GB
John Mankovich - Andover MA, US
Celia Patricia Shorrock - Cambridge, GB
Julia Elizabeth Thompson - Whittlesford, GB
Simon Nicholas Lennard - Linton, GB
Michael Roguska - Ashland MA, US
Michael White - Framingham MA, US
Boris Labkovsky - Marlborough MA, US
Jochen Salfeld - North Grafton MA, US
Alexander Robert Duncan - Little Shelford, GB
Simon Mark Brocklehurst - Fulbourn, GB
John Mankovich - Andover MA, US
Celia Patricia Shorrock - Cambridge, GB
Julia Elizabeth Thompson - Whittlesford, GB
Simon Nicholas Lennard - Linton, GB
Assignee:
Abbott Laboratories - Abbott Park IL
International Classification:
A61K 39/395, C12P 21/00, C12N 5/07, C12N 15/63, C40B 30/04, C07K 2/00, C07K 14/00, C07K 16/24, C07H 21/00, A61P 1/16, A61P 19/02, A61P 29/00, A61P 3/10, A61P 37/06, A61P 25/28, A61P 25/16, A61P 9/10, A61P 37/08, A61P 17/06, A61P 13/12, A61P 11/00, A61P 9/00, A61P 15/08, A61P 25/24, A61P 11/06, A61P 5/16, A61P 5/18, A61P 5/50
US Classification:
4241421, 435 696, 435325, 4353201, 506 9, 530300, 530350, 5303873, 5303879, 53038815, 536 235
Abstract:
Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
Human Antibodies That Bind Human Il-12
Human Antibodies That Bind Human Il-12
US Patent:
7504485, Mar 17, 2009
Filed:
Jul 1, 2004
Appl. No.:
10/884830
Inventors:
Jochen G. Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Cambridge, GB
Elaine J. Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Cambridge, GB
Elaine J. Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Assignee:
Abbott GmbH & Co., KG - Wiesbaden
International Classification:
C07K 16/24, A61K 39/395
US Classification:
53038823, 4241451
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Human Antibodies That Bind Human Il-12 And Methods For Producing
Human Antibodies That Bind Human Il-12 And Methods For Producing
US Patent:
6914128, Jul 5, 2005
Filed:
Mar 24, 2000
Appl. No.:
09/534717
Inventors:
Jochen Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Melrose MA, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Little Shelford, GB
Elaine Joy Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Stephen Smith - Ely, GB
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Melrose MA, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Little Shelford, GB
Elaine Joy Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Stephen Smith - Ely, GB
Assignee:
Abbott GmbH & Co. KG - Wiesbaden
International Classification:
C07K016/18, C07K016/24, C12P021/08
US Classification:
5303873, 5303871, 5303879, 53038815, 53038824, 5303892, 530351
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Methods For Inhibiting The Activity Of The P40 Subunit Of Human Il-12
Methods For Inhibiting The Activity Of The P40 Subunit Of Human Il-12
US Patent:
7883704, Feb 8, 2011
Filed:
Dec 22, 2006
Appl. No.:
11/645287
Inventors:
Jochen G. Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Hamden CT, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton Highlands MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Kantor - Pepperell MA, US
John Gawain Elvin - Meldreth, GB
Alexander Robert Duncan - Carton, GB
Elaine Joy Derbyshire - Crowthorne, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Rønde, DK
Sarah Leila Du Fou - Hitchen, GB
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Hamden CT, US
Daniel Edward Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton Highlands MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Kantor - Pepperell MA, US
John Gawain Elvin - Meldreth, GB
Alexander Robert Duncan - Carton, GB
Elaine Joy Derbyshire - Crowthorne, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Rønde, DK
Sarah Leila Du Fou - Hitchen, GB
Assignee:
Abbott GmbH & Co. KG - Wiesbaden
International Classification:
A61K 38/20, A61K 39/395, C07K 16/24, C12P 21/08
US Classification:
4241451, 53038823, 5303881, 5303891, 514 14, 4241301
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e. g. , in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Human Antibodies That Bind Human Tnfα
Human Antibodies That Bind Human Tnfα
US Patent:
8197813, Jun 12, 2012
Filed:
Mar 10, 2009
Appl. No.:
12/401469
Inventors:
Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westboro MA, US
Boris Labkovsky - Framingham MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Shrewsbury MA, US
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB
Deborah J. Allen - London, GB
Hendricus R. J. M. Hoogenboom - Hasselt, BE
Zehra Kaymakcalan - Westboro MA, US
Boris Labkovsky - Framingham MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Cambridge, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Shrewsbury MA, US
David Schoenhaut - Clifton NJ, US
Tristan J. Vaughan - Cambridge, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB
Assignee:
Abbott Biotechnology Ltd. - Hamilton
International Classification:
A61K 39/395, C07K 16/24
US Classification:
4241421, 4241451, 4241581, 53038815, 53038823
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Human Antibodies That Bind Human Tnfα
Human Antibodies That Bind Human Tnfα
US Patent:
7223394, May 29, 2007
Filed:
Mar 7, 2001
Appl. No.:
09/801185
Inventors:
Jochen G. Salfeld - North Grafton MA, US
Deborah J. Allen - Cambridge, GB
Hendricus R. J. M. Hoogenboom - Maastricht, BE
Zehra Kaymakcalan - Westboro MA, US
Boris Labkovsky - Framingham MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Comberton, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton MA, US
David Schoenhaut - Garfield NJ, US
Tristan J. Vaughan - Impington, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB
Deborah J. Allen - Cambridge, GB
Hendricus R. J. M. Hoogenboom - Maastricht, BE
Zehra Kaymakcalan - Westboro MA, US
Boris Labkovsky - Framingham MA, US
John A. Mankovich - Andover MA, US
Brian T. McGuinness - Comberton, GB
Andrew J. Roberts - Cambridge, GB
Paul Sakorafas - Newton MA, US
David Schoenhaut - Garfield NJ, US
Tristan J. Vaughan - Impington, GB
Michael White - Framingham MA, US
Alison J. Wilton - Cambridge, GB
Assignee:
Abbott Biotechnology Ltd - Hamilton
International Classification:
A61K 39/395
US Classification:
4241421, 4241451, 4241581, 53038815, 53038823, 5303892
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e. g. , K=10M or less), a slow off rate for hTNFα dissociation (e. g. , K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e. g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Human Antibodies That Bind Human Il-12 And Methods For Producing
Human Antibodies That Bind Human Il-12 And Methods For Producing
US Patent:
2009017, Jul 9, 2009
Filed:
Oct 16, 2008
Appl. No.:
12/253103
Inventors:
Jochen Salfeld - North Grafton MA, US
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Hamden MA, US
Daniel Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton Highlands MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Cambridge, GB
Elaine Joy Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Hamden MA, US
Daniel Tracey - Harvard MA, US
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton Highlands MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary NC, US
Nicholas W. Warne - Andover MA, US
Angela Myles - Andover MA, US
John Gawain Elvin - Cambridge, GB
Alexander Robert Duncan - Cambridge, GB
Elaine Joy Derbyshire - Royston, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Royston, GB
Sarah Leila Du Fou - Hitchen, GB
Assignee:
Abbott GMBH & Co., KG - Wiesbaden
International Classification:
A61K 39/395, C07K 16/18
US Classification:
4241331, 5303873
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Human Antibodies That Bind Human Il-12 And Methods For Producing
Human Antibodies That Bind Human Il-12 And Methods For Producing
US Patent:
2009026, Oct 29, 2009
Filed:
Feb 25, 2009
Appl. No.:
12/392614
Inventors:
Jochen SALFELD - North Grafton MA, US
Michael ROGUSKA - Ashland MA, US
Michael PASKIND - Sterling MA, US
Subhashis BANERJEE - Hamden MA, US
Daniel TRACEY - Harvard MA, US
Michael WHITE - Framingham MA, US
Zehra KAYMAKCALAN - Westborough MA, US
Boris LABKOVSKY - Marlborough MA, US
Paul SAKORAFAS - Newton Highlands MA, US
Geertruida M. VELDMAN - Sudbury MA, US
Amy VENTURINI - Lexington MA, US
Angela WIDOM - Acton MA, US
Stuart FRIEDRICH - Cary NC, US
Nicholas W. WARNE - Andover MA, US
Angela MYLES - Andover MA, US
John Gawain ELVIN - Cambridge, GB
Alexander Robert DUNCAN - Cambridge, GB
Elaine Joy DERBYSHIRE - Royston, GB
Sara CARMEN - Cambridge, GB
Stephen SMITH - Ely, GB
Thor Las HOLTET - Royston, GB
Sarah Leila DU FOU - Hitchen, GB
Michael ROGUSKA - Ashland MA, US
Michael PASKIND - Sterling MA, US
Subhashis BANERJEE - Hamden MA, US
Daniel TRACEY - Harvard MA, US
Michael WHITE - Framingham MA, US
Zehra KAYMAKCALAN - Westborough MA, US
Boris LABKOVSKY - Marlborough MA, US
Paul SAKORAFAS - Newton Highlands MA, US
Geertruida M. VELDMAN - Sudbury MA, US
Amy VENTURINI - Lexington MA, US
Angela WIDOM - Acton MA, US
Stuart FRIEDRICH - Cary NC, US
Nicholas W. WARNE - Andover MA, US
Angela MYLES - Andover MA, US
John Gawain ELVIN - Cambridge, GB
Alexander Robert DUNCAN - Cambridge, GB
Elaine Joy DERBYSHIRE - Royston, GB
Sara CARMEN - Cambridge, GB
Stephen SMITH - Ely, GB
Thor Las HOLTET - Royston, GB
Sarah Leila DU FOU - Hitchen, GB
Assignee:
ABBOTT GMBH & CO. KG - Wiesbaden
International Classification:
A61K 39/395, A61K 38/20, A61P 19/02, A61P 11/06, A61P 25/00, A61P 37/00
US Classification:
424 852, 4241301, 4241411
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.